Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 22;15(5):1215.
doi: 10.3390/v15051215.

Autoantibodies to Interferons in Infectious Diseases

Eugenia Quiros-Roldan  1 , Alessandra Sottini  2 , Simona Giulia Signorini  2 , Federico Serana  2 , Giorgio Tiecco  1 , Luisa Imberti  3
Affiliations
Review

Autoantibodies to Interferons in Infectious Diseases

Eugenia Quiros-Roldan et al. Viruses. .

Abstract

Anti-cytokine autoantibodies and, in particular, anti-type I interferons are increasingly described in association with immunodeficient, autoimmune, and immune-dysregulated conditions. Their presence in otherwise healthy individuals may result in a phenotype characterized by a predisposition to infections with several agents. For instance, anti-type I interferon autoantibodies are implicated in Coronavirus Disease 19 (COVID-19) pathogenesis and found preferentially in patients with critical disease. However, autoantibodies were also described in the serum of patients with viral, bacterial, and fungal infections not associated with COVID-19. In this review, we provide an overview of anti-cytokine autoantibodies identified to date and their clinical associations; we also discuss whether they can act as enemies or friends, i.e., are capable of acting in a beneficial or harmful way, and if they may be linked to gender or immunosenescence. Understanding the mechanisms underlying the production of autoantibodies could improve the approach to treating some infections, focusing not only on pathogens, but also on the possibility of a low degree of autoimmunity in patients.

Keywords: COVID-19; antiviral immunity; autoantibodies; cytokines; interferons.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Casanova J.L., Abel L. Mechanisms of viral inflammation and disease in humans. Science. 2021;374:1080–1086. doi: 10.1126/science.abj7965. - DOI - PMC - PubMed
    1. Liston A., Humblet-Baron S., Duffy D., Goris A. Human immune diversity: From evolution to modernity. Nat. Immunol. 2021;22:1479–1489. doi: 10.1038/s41590-021-01058-1. - DOI - PubMed
    1. Katze M.G., He Y., Gale M., Jr. Viruses and interferon: A fight for supremacy. Nat. Rev. Immunol. 2002;2:675–687. doi: 10.1038/nri888. - DOI - PubMed
    1. Elkon K., Casali P. Nature and functions of autoantibodies. Nat. Clin. Pract. Rheumatol. 2008;4:491–498. doi: 10.1038/ncprheum0895. - DOI - PMC - PubMed
    1. Bastard P., Rosen L.B., Zhang Q., Michailidis E., Hoffmann H.H., Zhang Y., Dorgham K., Philippot Q., Rosain J., Béziat V., et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585. doi: 10.1126/science.abd4585. - DOI - PMC - PubMed